4 completed. 4 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 4 | Completed 4 |
Follow Drug Abuse: new trials by email Literature Review of Drug Abuse trials Research Report on Drug Abuse
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Preference for Subutex® (Buprenorphine) Versus Suboxone® (Buprenorphine/Naloxone) in Opioid Dependent Patients on Subutex® (Study P05094)(COMPLETED) buprenorphine, buprenorphine/naloxone - Opiate-related Disorders, Opiate Dependence | Phase 4 | Completed | Indivior Inc. | 60 | 2007-07-01 | 2023-03-20 |
| Integration of Buprenorphine Into HIV Clinical Settings - Primary Care Model (PCM) Services will be provided at one site, Services remain dispersed; i.e., not centralized to one-location or provider. - Buprenorphine, HIV | Phase 4 | Completed | Yale University | 60 | 2005-08-01 | 2015-07-24 |
| Improving Hepatitis C Treatment in Injection Drug Users Pegylated Interferon and Ribavirin, Psychosocial, On-site (MMT Clinic) HCV evaluation and treatment - Hepatitis C, Liver Diseases | Phase 4 | Completed | State University of New York - Upstate Medical University | 111 | 2003-09-01 | 2013-04-24 |
| Reinforcement-Based Treatment and Abstinence-Contingent Housing for Drug Abusers Reinforcement Based Treatment - Drug Abuse | Phase 4 | Completed | National Institute on Drug Abuse (NIDA) | 463 | 2002-08-01 | 2017-01-11 |
Substance-Related Disorders (4) · Opioid-Related Disorders (2) · Alcoholism (1) · Digestive System Diseases (1) · Hepatitis C (1) · Liver Diseases (1) · Patient Acceptance of Health Care (1) · Patient Compliance (1)
Chemically-Induced Disorders (4) · Mental Disorders (4) · Narcotic-Related Disorders (2) · Alcohol-Related Disorders (1) · Behavior (1) · Blood-Borne Infections (1) · Communicable Diseases (1) · Flaviviridae Infections (1) · Health Behavior (1) · Hepatitis (1) · Hepatitis, Viral, Human (1) · Infections (1) · RNA Virus Infections (1) · Treatment Adherence and Compliance (1) · Virus Diseases (1)
Buprenorphine (1) · Buprenorphine, Naloxone Drug Combination (1) · Ribavirin (1) · Therapeutics (1)
Indivior Inc. (1) · National Institute on Drug Abuse (NIDA) (1) · State University of New York - Upstate Medical University (1) · Yale University (1)
United States (3)
Frederick Altice, MD (1) · Maxine Stitzer, Ph.D. (1) · Steven L Batki, MD (1)
R01DA016764 (1)